{
  "slug": "retatrutide-weight-loss",
  "round": 2,
  "date": "2026-10-14",
  "authoring_model": "Sol 6.1",
  "reviewer": "Claude Opus 5.5 (Anthropic)",
  "canonical_path": "hsef_v53_traffic_first_five_2026-10-12/retatrutide-weight-loss/retatrutide-weight-loss.review.md",
  "level_before": "Ε",
  "level_after": "Ε",
  "confidence_before": "Moderate",
  "confidence_after": "Moderate",
  "role_before": "reinforcing / stabilizing factor",
  "role_after": "reinforcing / stabilizing factor",
  "msd_before": {
    "momentum": "Decisive work underway",
    "stability": "Uncertain",
    "divergence": "Contested"
  },
  "msd_after": {
    "momentum": "Decisive work underway",
    "stability": "Uncertain",
    "divergence": "Contested"
  },
  "counts": {
    "critical": 0,
    "major": 3,
    "minor": 2,
    "editorial": 1,
    "total": 6
  },
  "pmids_checked": 66,
  "pmids_in_references": 60,
  "pmids_failed": 0,
  "claims_spot_checked": 11,
  "claims_misattributed": 1,
  "validator": "PASS - 0 fail, 0 warn, 31 pass",
  "findings": [
    {
      "id": "B1",
      "severity": "Major",
      "type": "misstatement (understatement of a safety finding)",
      "location": "Evidence card [57]; decisive-perturbation entry [57]; Consensus reconciliation; scorecard evidence rows for PMID 39509151",
      "original": "Original semaglutide test-purchase study finds mislabeled quantities and selected-vial analytical/endotoxin concerns, plus nondelivery scams.",
      "corrected": "Original semaglutide test-purchase study finds mislabeled quantities, measured purity of 7.7-14.37% against a 99% label claim, and endotoxin detected in all three delivered vials, plus nondelivery scams.",
      "evidence": "PMID 39509151 Results: endotoxin in all three delivered vials (<2.8658 EU/mg, <2.1645 EU/mg, and a measured 8.9511 EU/mg from SemaSpace); purity 7.7-14.37% against a 99% label claim; content exceeded label by 28.56-38.69%. 'Selected-vial' understated a contamination finding in a consumer-safety context. The review's correct separate observation that the abstract presents two upper bounds as point values is retained."
    },
    {
      "id": "B2",
      "severity": "Major",
      "type": "rendering defect",
      "location": "throughout, approximately 140 sites",
      "original": "glued words and numerals, e.g. 'TheJMIRabstractsaysendotoxin detected in allsamples', 'FDAcurrentapprovalstatus isauxiliaryregulatorycontext', 'randomizes2339adults', 'dulaglutide1.5mg', 'Step3requires', 'registered24-72weeks'",
      "corrected": "inter-word and numeral spacing restored; trial names normalised to SURMOUNT-1/-5, STEP-1/-2/-5/-9, TRIUMPH-1/-2",
      "evidence": "Known builder rendering defect; in this review it affected whole words including a consumer-safety paragraph. No numeric value, unit, identifier or claim direction altered."
    },
    {
      "id": "B3",
      "severity": "Minor",
      "type": "misspelling",
      "location": "Research timeline, 2023 entry",
      "original": "addsdulagutide active comparison",
      "corrected": "adds dulaglutide active comparison",
      "evidence": "Comparator drug name misspelled."
    },
    {
      "id": "B4",
      "severity": "Minor",
      "type": "rendering defect",
      "location": "Evidence cards, 6 sites",
      "original": "ErratumIn: PMID38945123",
      "corrected": "Erratum in: PMID 38945123",
      "evidence": "Known builder defect in erratum strings. All six erratum PMIDs were verified as Published Errata and are correctly attached to parent rows."
    },
    {
      "id": "B5",
      "severity": "Editorial",
      "type": "rendering defect",
      "location": "Proposed decisive experiments and access/status fields",
      "original": "doubled field-separator full stops",
      "corrected": "single full stop",
      "evidence": "Template concatenation artifact."
    },
    {
      "id": "B6",
      "severity": "Major",
      "type": "rendering defect / misstatement",
      "location": "AT A GLANCE, 'Best-supported rival' line",
      "original": "Best-supported rival: Supervised retatrutide exposure produces clinical weight loss.",
      "corrected": "Best-supported rival: GLP1-based appetite suppression produces clinical weight loss (Ε) — the best-supported model that is not the nominal; the nominal still leads the tournament.",
      "evidence": "Known renderer defect: the field printed competing_models.models_evaluated[0], which in this score card is the nominal model (is_nominal true, rank_in_tournament 1). As written it offered the hypothesis itself as its own leading rival. Score card rank and nominal flags are correct and were not changed."
    }
  ],
  "rejected_findings": [
    "Epsilon rather than Zeta for SC2: framework states replications of one line make a confident Epsilon, not a Zeta; mouse receptor work is not an independent line on the human clinical claim.",
    "Epsilon setting the headline: the central claim is itself registered to trial-eligible adults, so SC2's scope matches it; the scope-restriction objection does not apply.",
    "Causal role at derivation step 5: primary driver considered and rejected for want of retatrutide-specific withdrawal and rate-limitation evidence.",
    "Momentum 'Decisive work underway': artifact names the TRIUMPH registrational and outcomes programme.",
    "80-week TRIUMPH results treated as corroboration outside the registered 24-72-week gate rather than redefining it.",
    "SC4 at Alpha: checked in both directions; the review neither asserts grey-market equivalence nor uniform danger, and distinguishes absence of evidence from measurement.",
    "No citation-year deviation beyond one year from PubMed; no collective-author rendering defect in this reference list.",
    "Confidence band Moderate verified against the framework's confidence text rather than access depth: High requires extensive independent replication across labs, models and assay modalities, and the retatrutide trials are one sponsor, one modality and one causal line.",
    "No false-approval boilerplate and no false provenance clause present; no earlier adversarial approval is asserted."
  ],
  "residual_limitations": "Five of sixty sources examined beyond abstract depth; the two largest retatrutide trial bodies were not audited in full, so the 80-week figures rest on abstracts. No grey-market retatrutide product has been analytically tested or linked to clinical outcomes in any examined source. No direct randomized comparison against obesity-dose semaglutide or tirzepatide exists.",
  "propagation": {
    "propagate_to": [
      "hsef_v53_topical_all_22_2026-10-13/cycles/hsef_v53_traffic_first_five_share_2026-10-13/retatrutide-weight-loss/retatrutide-weight-loss.review.md",
      "hsef_v53_traffic_first_five_share_2026-10-13/retatrutide-weight-loss/retatrutide-weight-loss.review.md"
    ],
    "divergent_copies": []
  },
  "approval": "Approved as revised. — Claude Opus 5.5 (Anthropic), 2026-10-14."
}